Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LZAGY vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MXCT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

MXCT Overall Winner 6-Pillar Tally: LZAGY 0 – 5 MXCT (1 Tie) Matrix Metrics: LZAGY 3 – 5 MXCT

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over LZAGY (LZAGY) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LZAGY carries a Unified Composite Score of 44.5/100 (HOLD) at $77.10 (N/M Forward P/E, N/A operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Composite vs. Pillar Nuance: While LZAGY currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. N/A operating margin) and revenue trajectory (+48.7% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LZAGY vs MXCT
LZAGY US Equity
LZAGY
Institutional Equity
$77.10
-2.58% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.45β · 17% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 18.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.7 · SMA20: $79.03 · SMA50: $73.42
MXCT NASDAQ Head-to-Head Winner
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (LZAGY 0 – 5 MXCT)

Columns: Metric · LZAGY · MXCT
1. Valuation Multiples MXCT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale MXCT
Revenue Growth (YoY) N/A +48.7%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $34M
Market Cap N/A $132.2M
3. Profitability & Quality MXCT
Gross Margin N/A 81.0%
Operating Margin N/A -85.5%
Net Profit Margin N/A -81.4%
Return on Equity (ROE) N/A -16.9%
4. Balance Sheet & Cash Flow MXCT
Cash Generation (TTM) N/A -$24M
Cash Flow Margin N/A -69.2%
Net Cash / Leverage N/A ROE $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LZAGY (3) vs MXCT (5)
Institutional Metric LZAGY MXCT Criterion Row Edge
Market Capitalization
Scale
N/A $132.2M Larger Scale MXCT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +48.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
N/A -85.5% Higher Margin MXCT
Net Profit Margin
Profitability
N/A -81.4% Higher Margin MXCT
Return on Equity (ROE)
Capital Efficiency
N/A -16.9% Higher ROE MXCT
52-Week Range Position
Momentum
77% ($59–$83) 63% ($1–$2) Stronger Trend LZAGY
Beta / 30D Volatility
Risk Regime
0.45β · 17% Vol 1.19β · 96% Vol Lower Realized Risk LZAGY
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite LZAGY
Trailing 12M Revenue (USD)
Operating Scale
N/A $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LZAGY +4.73 pp
LZAGY: +0.53% · MXCT: -4.2%
3M Horizon LZAGY +6.65 pp
LZAGY: +5.21% · MXCT: -1.44%
6M Horizon MXCT +9.04 pp
LZAGY: +22.69% · MXCT: +31.73%
1Y Horizon LZAGY +35.95 pp
LZAGY: +16.54% · MXCT: -19.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LZAGY vs MXCT. Trailing 12-month operating profitability (LZAGY N/A vs MXCT -85.5%) and valuation multiples (LZAGY N/M vs MXCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LZAGY ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
MXCT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$34M
Gross Margin81.0%
Op. Margin-85.5%
ROE / Fwd P/E-16.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LZAGY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LZAGY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LZAGY Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LZAGY vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over LZAGY (LZAGY) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LZAGY carries a Unified Composite Score of 44.5/100 (HOLD) at $77.10 (N/M Forward P/E, N/A operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Composite vs. Pillar Nuance: While LZAGY currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. N/A operating margin) and revenue trajectory (+48.7% vs. N/A YoY).

MXCT leads the Growth & Scale pillar: LZAGY posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). On trailing 12-month operating scale, LZAGY generates N/A in USD-normalized revenue versus $34M for MXCT. In operating R&D and SG&A reinvestment, LZAGY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

MXCT screens cheaper on headline valuation multiples. LZAGY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LZAGY (N/A ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, LZAGY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 17% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.